+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

U.S. Veterinary Orthopedic Medicine Market Size, Share & Trends Analysis Report by Product (Biologics, Viscosupplements, Pharmaceuticals), Animal Type, Application, Route Of Administration, End-use, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 120 Pages
  • December 2023
  • Region: United States
  • Grand View Research
  • ID: 5921086
The U.S. veterinary orthopedic medicine market size is expected to reach USD 814.51 million by 2030, registering a CAGR of 7.2% from 2024 to 2030. The market is primarily driven by the increasing pet population, adoption of pet insurance, rising prevalence of diseases among animals, and advancements in veterinary medicine.

For instance, in October 2023, the FDA approved Librela (bedinvetmab injection), making it the first monoclonal antibody for treating osteoarthritis-related pain in dogs. In addition, in April 2022, American Regent Animal Health, a division of American Regent, Inc., received FDA approval to extend the shelf life of Adequan Canine and Adequan i.m. The expiration date for both products was increased from 24 months to 36 months from the date of manufacture.

Key players in the veterinary orthopedic medicine market are engaging in strategic initiatives like product launches, collaborations, and acquisitions to make their market presence more prominent, impelling market growth. In September 2022, Zoetis acquired Jurox, a private animal health company specializing in veterinary medicines for livestock and companion animals. The deal, finalized in August 2021, included Jurox's operations in Australia and regional offices in the U.S., Canada, and the UK. Such initiatives are anticipated to drive market growth.

For instance, in October 2023, Athersys, Inc. (ATHX), a cell therapy and regenerative medicine company, entered into a licensing agreement with Ardent Animal Health. With this move, Athersys, known for its work with MultiStem (invimestrocel) in critical care, entered the field of animal health. This collaboration with Ardent, a veterinary biotech firm specializing in regenerative medicine and cancer therapies for animals, highlights Athersys’ commitment to advancing veterinary care.

Some key impacts of the pandemic and respective lockdowns on the market include dampened growth, decreased sales, supply chain disruptions, and operational challenges. However, the pandemic also propelled concerns over animal health and welfare, strengthened the pet parent and animal bond, and increased pet adoption. Moreover, the market witnessed an improved medicalization rate, pet expenditure, and adoption of pet insurance.

Increasing pet humanization and improved diagnostic rates were other positive impacts of the COVID-19 pandemic on the veterinary sector. In 2021, the market recorded increased demand and sale of veterinary medicines, including orthopedic medicines. In 2022, other macroeconomic uncertainties, such as global recession and cost inflation, adversely impacted the business. However, as the underlying market drivers remain unchanged owing to an increasing prevalence of orthopedic disorders in dogs and horses, the market is estimated to grow notably over the forecast period.

U.S. Veterinary Orthopedic Medicine Market Report Highlights

  • Based on product, pharmaceuticals segment dominated the market, accounting for a share of 46.72% in 2023. Pharmaceutical treatments for orthopedic diseases in pets, such as Non-steroidal Anti-inflammatory Drugs (NSAIDs) and pain relievers, have been widely used and established as effective treatments for managing pain and inflammation. On the other hand, the viscosupplements segment is anticipated to grow at the fastest CAGR of 8.23% during the forecast period
  • Based on animal type, the market is segmented into dogs and horses. The dogs segment dominated the market, accounting for a share of 51.98% in 2023. It is also anticipated to grow at the fastest CAGR of 7.80% in the coming decade
  • Based on application, the osteoarthritis segment accounted for the largest share of 60.65% of the market in 2023. The other segment is expected to grow at the fastest CAGR of 9.39% over the forecast period
  • Based on route of administration, the market is segmented into injectable, oral, and others (e.g., topical). The injectable segment dominated the market, accounting for a share of 60.40% in 2023. The others (e.g., topical) segment is anticipated to grow at the fastest CAGR of 8.22% in the coming decade
  • On the basis of end-use, veterinary clinics & hospitals segment accounted for the largest share of 53.59% of the market in 2023. The other segment is expected to grow at the fastest CAGR of 8.68% over the forecast period

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation And Scope
1.1.1 Regional Scope
1.1.2 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Internal database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information/data Analysis
1.4.1 Information Analysis
1.5 Market Formulation & Visualization
1.6 Data Validation & Publishing
1.7 Model Details
1.7.1 Approach 1: Commodity Flow Analysis
1.7.1.1 Hybrid Market Estimation Model
1.7.2 Global Market: Cagr Calculation
1.7.3 Approach 2: Parent Market Analysis
1.8 List Of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Segment Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 U.S. Veterinary Orthopedic Medicine Market Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Analysis
3.2 U.S. Veterinary Orthopedic Medicine Market Dynamics
3.3 Market Driver Impact Analysis
3.3.1 Increasing Incidence Of Orthopedic Problems
3.3.2 Growing Uptake Of Pet Insurance
3.3.3 Increase In Canine & Equine Population
3.3.4 Advancements In Veterinary Orthopedic Medicine
3.3.5 Supportive Initiatives
3.4 Market Restraint Impact Analysis
3.4.1. High Cost Of Treatment
3.5 Market Opportunity Analysis
3.6 Market Challenge Analysis
3.7 U.S. Veterinary Orthopedic Medicine Market: Porter’s 5 Forces Analysis
3.7.1 Bargaining Power Of Buyers: High
3.7.2 Bargaining Power Of Suppliers: Moderate - Low
3.7.3 Threat Of New Entrants: High
3.7.4 Threat Of Substitutes: Low - Moderate
3.7.5 Competitive Rivalry: High
3.8 U.S. Veterinary Orthopedic Medicine Market: Pestel Analysis
3.8.1 Political
3.8.2 Economic
3.8.3 Social
3.8.4 Technological
3.8.5 Environmental
3.8.6 Legal
3.9 Pet Owner Demographics & Behavior Analysis
3.10 Impact Of Covid-19 Pandemic, Recession & Inflation
3.11 U.S. Estimated Pet Dog & Horse Population (Million), 2018 To 2030
3.12 Estimated Number Of Intra-articularly Injected Canine Joints, 2022
Chapter 4 Product Estimates & Trend Analysis, 2018-2030 (USD Million)
4.1 U.S. Veterinary Orthopedic Medicine Market By Product: Key Takeaways
4.2 Product Movement Analysis & Market Share, 2022 & 2030
4.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecast, By Product (USD Million)
4.3.1 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Biologics (USD Million)
4.3.2 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Pharmaceuticals (USD Million)
4.4 Biologics
4.4.1 Biologics Market Estimates And Forecasts, 2018-2030 (USD Million)
4.4.2 Stem Cells
4.4.2.1 Stem Cells Market Estimates And Forecasts, 2018-2030 (USD Million)
4.4.3 Platelet-rich Plasma (Prp)
4.4.3.1 Platelet-rich Plasma (Prp) Market Estimates And Forecasts, 2018-2030 (USD Million)
4.4.4 Other Biologics
4.4.4.1 Other Biologics Market Estimates And Forecasts, 2018-2030 (USD Million)
4.5 Viscosupplements
4.5.1 Viscosupplements Market Estimates And Forecasts, 2018-2030 (USD Million)
4.6 Pharmaceuticals
4.6.1 Pharmaceuticals Market Estimates And Forecasts, 2018-2030 (USD Million)
4.6.2 Steroids
4.6.2.1 Steroids Market Estimates And Forecasts, 2018-2030 (USD Million)
4.6.3 Nsaids
4.6.3.1 Nsaids Market Estimates And Forecasts, 2018-2030 (USD Million)
4.6.4 Others
4.6.4.1 Others Market Estimates And Forecasts, 2018-2030 (USD Million)
Chapter 5 Application Estimates & Trend Analysis, 2018-2030 (USD Million)
5.1 U.S. Veterinary Orthopedic Medicine Market By Solutions: Key Takeaways
5.2 Application Movement Analysis & Market Share, 2022 & 2030
5.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecast, By Application (USD Million)
5.4 Osteoarthritis (Oa)
5.4.1 Osteoarthritis Market Estimates And Forecasts, 2018-2030 (USD Million)
5.4.2 Degenerative Joint Disease
5.4.2.1 Degenerative Joint Disease Market Estimates And Forecasts, 2018-2030 (USD Million)
5.4.3 Others
5.4.3.1 Others Market Estimates And Forecasts, 2018-2030 (USD Million)
Chapter 6 Route Of Administration Estimates & Trend Analysis, 2018-2030 (USD Million)
6.1 U.S. Veterinary Orthopedic Medicine Market By Route Of Administration: Key Takeaways
6.2 Route Of Administration Movement Analysis & Market Share, 2022 & 2030
6.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecast, By Route Of Administration (USD Million)
6.3.1 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Injectable (USD Million)
6.4 Injectable
6.4.1 Injectable Market Estimates And Forecasts, 2018-2030 (USD Million)
6.4.2 Intra-muscular
6.4.3 Intra-muscular Market Estimates And Forecasts, 2018-2030 (USD Million)
6.4.4 Intra-articular
6.4.5 Intra-articular Market Estimates And Forecasts, 2018-2030 (USD Million)
6.4.6 Others
6.4.7 Others Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5 Oral
6.5.1 Oral Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6 Others
6.6.1 Others Market Estimates And Forecasts, 2018-2030 (USD Million)
Chapter 7 Animal Type Estimates & Trend Analysis, 2018-2030 (USD Million)
7.1 U.S. Veterinary Orthopedic Medicine Market, By Animal Type: Key Takeaways
7.2 Dogs Movement Analysis & Market Share, 2022 & 2030
7.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Animal Type (USD Million)
7.3.1 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts, By Dogs (USD Million)
7.4 Dogs
7.4.1 Dogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.4.2 Small Breeds
7.4.2.1 Small Breeds Market Estimates And Forecasts, 2018-2030 (USD Million)
7.4.3 Medium-sized Breeds
7.4.3.1 Medium-sized Breeds Market Estimates And Forecasts, 2018-2030 (USD Million)
7.4.4 Large Breeds
7.4.4.1 Large Breeds Market Estimates And Forecasts, 2018-2030 (USD Million)
7.5 Horses
7.5.1 Horses Market Estimates And Forecasts, 2018-2030 (USD Million)
Chapter 8 End-use Estimates & Trend Analysis, 2018-2030 (USD Million)
8.1 U.S. Veterinary Orthopedic Medicine Market By End-use: Key Takeaways
8.2 End-use Movement Analysis & Market Share, 2022 & 2030
8.3 U.S. Veterinary Orthopedic Medicine Market Estimates & Forecasts By End-use (USD Million)
8.4 Veterinary Hospitals & Clinics
8.4.1 Veterinary Hospitals & Clinics Market Estimates And Forecasts, 2018-2030 (USD Million)
8.5 At-home
8.5.1 At-home Market Estimates And Forecasts, 2018-2030 (USD Million)
8.6 Others
8.6.1. Others Market Estimates And Forecasts, 2018-2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Market Participant Categorization
9.2. Company Market Position Analysis/ Heap Map Analysis
9.3. Strategy Mapping
9.3.1. Mergers & Acquisitions
9.3.2. Partnerships & Collaborations
9.3.3. Others
9.4. Company Profiles
9.4.1. Zoetis
9.4.1.1. Participant’s Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. Ardent Animal Health, LLC
9.4.2.1. Participant’s Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. Enso Discoveries
9.4.3.1. Participant’s Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. Arthrex, Inc.
9.4.4.1. Participant’s Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. VetStem, Inc.
9.4.5.1. Participant’s Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Contura Vet US
9.4.6.1. Participant’s Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. MEDREGO LLC
9.4.7.1. Participant’s Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. PetVivo Holdings, Inc. (Spryng)
9.4.8.1. Participant’s Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. T-Cyte Therepeutics
9.4.9.1. Participant’s Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives
9.4.10. Boehringer Ingelheim Animal Health USA Inc.
9.4.10.1. Participant’s Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Benchmarking
9.4.10.4. Strategic Initiatives
9.4.11. American Regent, Inc.
9.4.11.1. Participant’s Overview
9.4.11.2. Financial Performance
9.4.11.3. Product Benchmarking
9.4.11.4. Strategic Initiatives
9.4.12. Bimeda U.S.
9.4.12.1. Participant’s Overview
9.4.12.2. Financial Performance
9.4.12.3. Product Benchmarking
9.4.12.4. Strategic Initiatives
9.4.13. Nucleus ProVets
9.4.13.1. Participant’s Overview
9.4.13.2. Financial Performance
9.4.13.3. Product Benchmarking
9.4.13.4. Strategic Initiatives
Chapter 10. Key Takeaways
List of Tables
Table 1 List of secondary sources
Table 2 Impact of COVID-19, recession, & inflation on some key players
Table 3 U.S. veterinary orthopedic medicine market estimates and forecast, by product, 2018-2030 (USD million)
Table 4 U.S. veterinary orthopedic medicine market estimates and forecast, by Biologics, 2018-2030 (USD million)
Table 5 U.S. veterinary orthopedic medicine market estimates and forecast, by Pharmaceuticals, 2018-2030 (USD million)
Table 6 U.S. veterinary orthopedic medicine market estimates and forecast, by application, 2018-2030 (USD million)
Table 7 U.S. veterinary orthopedic medicine market estimates and forecast, by route of administration, 2018-2030 (USD million)
Table 8 U.S. veterinary orthopedic medicine market estimates and forecast, by injectable, 2018-2030 (USD million)
Table 9 U.S. veterinary orthopedic medicine market estimates and forecast, by animal type, 2018-2030 (USD million)
Table 10 U.S. veterinary orthopedic medicine market estimates and forecast, by dogs, 2018-2030 (USD million)
Table 11 U.S. veterinary orthopedic medicine market estimates and forecast, by end-use, 2018-2030 (USD million)
Table 12 Participants' overview
Table 13 Financial performance
Table 14 Products benchmarking
Table 15 Key companies undertaking acquisitions.
Table 16 Key companies launching new products.
Table 17 Key companies undertaking partnership & collaboration strategies.
Table 18 Key market players initiating expansion.
List of Figures
Figure 1 U.S. Veterinary Orthopedic Medicine Market segmentation
Figure 2 Market research process
Figure 3 Information procurement
Figure 4 Primary research pattern
Figure 5 Data Analysis Models
Figure 6 Market Formulation and Validation
Figure 7 Data Validating & Publishing
Figure 8 General methodology for commodity flow analysis of animal health market
Figure 9 Commodity flow analysis
Figure 10 Parent market analysis
Figure 11 Market snapshot
Figure 12 Segment snapshot
Figure 13 Segment snapshot
Figure 14 Competitive landscape snapshot
Figure 15 Parent Market Analysis, 2023 (USD million)
Figure 16 Ancillary market outlook, 2023
Figure 17 U.S. Veterinary Orthopedic Medicine Market Dynamics
Figure 18 U.S. Veterinary Orthopedic Medicine Market: PORTER’s analysis
Figure 19 U.S. Veterinary Orthopedic Medicine Market: PESTEL analysis
Figure 20 U.S. Veterinary Orthopedic Medicine Market by product: Key takeaways
Figure 21 U.S. Veterinary Orthopedic Medicine Market by Product, Market share, 2023 & 2030
Figure 22 Biologics market, 2018-2030 (USD million)
Figure 23 Stem cells market, 2018-2030 (USD million)
Figure 24 PRP market, 2018-2030 (USD million)
Figure 25 Other biologics market, 2018-2030 (USD million)
Figure 26 Viscosupplements market, 2018-2030 (USD million)
Figure 27 Pharmaceuticals market, 2018-2030 (USD million)
Figure 28 Steroids market, 2018-2030 (USD million)
Figure 29 NSAIDS market, 2018-2030 (USD million)
Figure 30 Others market, 2018-2030 (USD million)
Figure 31 U.S. veterinary orthopedic medicine market by application: Key Takeaways
Figure 32 U.S. veterinary orthopedic medicine market by application, market share, 2023 & 2030
Figure 33 Osteoarthritis market, 2018-2030 (USD million)
Figure 34 Degenerative joint disease market, 2018-2030 (USD million)
Figure 35 Platelet-Rich Plasma (PRP) market, 2018-2030 (USD million)
Figure 36 U.S. veterinary orthopedic medicine market by route of administration: Key Takeaways
Figure 37 U.S. veterinary orthopedic medicine market by route of administration, market share, 2023 & 2030
Figure 38 Injectable market, 2018-2030 (USD million)
Figure 39 Intra-Muscular market, 2018-2030 (USD million)
Figure 40 Intra-Articular market, 2018-2030 (USD million)
Figure 41 Others market, 2018-2030 (USD million)
Figure 42 Oral market, 2018-2030 (USD million)
Figure 43 Others market, 2018-2030 (USD million)
Figure 44 U.S. veterinary orthopedic medicine market, by animal type: Key takeaways
Figure 45 U.S. veterinary orthopedic medicine market, by animal type: Market share, 2023 & 2030
Figure 46 Dogs market, 2018-2030 (USD million)
Figure 47 Small breeds market, 2018-2030 (USD million)
Figure 48 Medium-sized breeds market, 2018-2030 (USD million)
Figure 49 Large breeds market, 2018-2030 (USD million)
Figure 50 Horses market, 2018-2030 (USD million)
Figure 51 U.S. veterinary orthopedic medicine market, by end-use: Key takeaways
Figure 52 U.S. veterinary orthopedic medicine market, by end-use, market share, 2023 & 2030
Figure 53 Veterinary hospitals & clinics market, 2018-2030 (USD million)
Figure 54 At-home market, 2018-2030 (USD million)
Figure 55 Others market, 2018-2030 (USD million)
Figure 56 Market Participant categorization
Figure 57 Strategic Framework

Companies Mentioned

  • Zoetis
  • Ardent Animal Health, LLC
  • Enso Discoveries
  • Arthrex, Inc.
  • VetStem, Inc.
  • Contura Vet US
  • MEDREGO LLC
  • PetVivo Holdings, Inc. (Spryng)
  • T-Cyte Therepeutics
  • Boehringer Ingelheim Animal Health USA Inc.
  • American Regent, Inc.
  • Bimeda U.S.
  • Nucleus ProVets

Methodology

Loading
LOADING...

Table Information